This study was undertaken to determine whether patients with unexplained, elevated second-trimester maternal serum human chorionic gonadotropin (hCG) concentrations are at increased risk of adverse pregnancy outcome. In a retrospective study, perinatal outcomes of 355 patients showing elevated second-trimester maternal serum hCG concentrations (> or = 2.0 multiples of median) were compared with those of patients from the same clinic showing normal values (N = 4935), using multiple regression analysis. The effects of variables such as socioeconomic status on pregnancy outcome were taken into account. Between the study subjects and controls, statistically significant differences were observed as regards low birthweight (odds ratio [OR] 1.56, 95% confidence interval [CI]: 1.00-2.44) and intrauterine growth retardation (OR 1.46, 95% CI: 1.03-2.06). Differences in the frequencies of preterm delivery, fetal/perinatal death, fetal distress, or admission to a specific infant care unit were not statistically significant. Preeclampsia (OR 1.76, 95% CI: 1.16-2.70) and velamentous umbilical cord insertion (OR 2.62, 95% CI: 1.47-4.69) were particularly involved in the pathophysiology. Elevated maternal serum hCG concentrations were associated with an increased risk of adverse pregnancy outcome. This resulted mainly from preeclampsia and velamentous umbilical cord insertion. The optimal perinatal management strategy for patients with unexplained elevated hCG levels is not yet resolved. In view of our results, the possibility of preeclampsia and abnormal insertion should be taken into account. In future studies, increased surveillance should be offered in cases showing abnormal uterine artery velocimetric results or abnormal umbilical cord insertion in color Doppler examination to evaluate whether and to what extent intensive monitoring decreases perinatal morbidity in high-risk pregnancies followed because of unexplained, elevated hCG. Until further data are available, no specific recommendations can be made.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-2007-994384 | DOI Listing |
Reprod Sci
January 2025
Department of Anatomy, Institute of Medical Science, Banaras Hindu University, Varanasi, 221005, India.
Recurrent pregnancy loss (RPL), defined as two or more consecutive miscarriages before 20 weeks of gestation, affects 1-2% of couples worldwide. Pro-inflammatory cytokines, such as TNF-α, IL-1β and IL-6 play critical roles in early pregnancy, while anti-inflammatory cytokines like TGF-β and IL-10 promote immune tolerance to prevent harmful inflammatory responses that play important role in placental and fetal development. This aim of the study is to analyse the levels of inflammatory cytokines in blood serum from RPL patients and healthy women (control).
View Article and Find Full Text PDFMed Oncol
January 2025
Laboratory of Molecular Toxicology, Faculty of Nature and Life Sciences, University of Jijel, 18000, Jijel, Algeria.
The current study aimed to assess the preventive effects of aqueous leaf extract of Pistacia lentiscus (ALEPL) against Oxaliplatin (OXA)-induced DNA damage, hepatic injury, and oxidative stress. The in vitro cytotoxic and genotoxic effects of OXA and ALEPL on HCT116 colon cancer cells were evaluated using the MTT (Tetrazolium salt reduction) assay and comet assay. The in vivo study involved 24 female NMRI (Naval Medical Research Institute) mice that were equally divided into four groups as follows: Control group, ALEPL-treated group (100 mg/kg), OXA-treated group (7 mg/kg), and ALEPL-treated group (100mg/kg) + OXA (7mg/kg).
View Article and Find Full Text PDFBMJ Open
January 2025
Department of Obstetrics and Gynaecology, Uganda Martyrs University, Mother Kevin Postgraduate Medical School, Nsambya Campus, Kampala, Uganda.
Objective: There is a dearth of published data on the vitamin D status of the Ugandan population; the objective of the study was to determine the prevalence of vitamin D deficiency among pregnant women in Uganda and its associations with maternal characteristics and adverse foetal-maternal outcomes.
Study Design And Setting: We conducted a cross-sectional study on pregnant women admitted to a tertiary referral hospital in Kampala, Uganda for delivery during the study period from July to December 2023.
Participants: The study was conducted on 351 pregnant women aged ≥18 years who consented to participate in the study, who had a single intrauterine pregnancy and a gestational age greater than 26 weeks, and who delivered at St.
J Gynecol Obstet Hum Reprod
January 2025
Laboratoire de Dépistage Périnatal, Centre de Biologie Pathologie et Génétique, Centre Hospitalier Universitaire, Lille, France. Electronic address:
Background: In France, legislation concerning pregnancy monitoring only considers screening for Down syndrome (T21), while the contingent introduction of the circulating cell free DNA test (DPNI) also allows screening for trisomies 13 and 18 with similar performances.
Methods: We retrospectively studied more than 800,000 patients among whom 7971 presented serum markers suggestive of T18 (but without increased risk of T21), of which 438 benefited from NIPT and of a complete pregnancy follow-up.
Results: We show that the use of a specific risk calculation for T18 would have improve the relevance of the prescription.
Background: Rhabdomyoma is the most common cardiac tumor in fetal life. It has frequent association with tuberous sclerosis complex and may lead to heart failure, a potentially fatal condition. The use of transplacental sirolimus, a mTOR inhibitor, has emerged as a novel treatment in symptomatic fetal rhabdomyomas, there are, though, only few cases described.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!